+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Glaucoma - Epidemiology Forecast to 2030

  • ID: 5322341
  • Report
  • May 2021
  • Region: Global
  • 156 pages
  • DelveInsight
This ‘Glaucoma - Epidemiology Forecast-2030' report delivers an in-depth understanding of the Glaucoma , historical and forecasted epidemiology as well as the Glaucoma trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Glaucoma Disease Understanding


According to the American Academy of Ophthalmology, glaucoma describes a group of conditions in which there is characteristic cupping of the optic disc with corresponding visual field defects due to retinal ganglion cell loss. It is a progressive condition and the most common cause of irreversible blindness worldwide. The two major categories of glaucoma are open-angle glaucoma and narrow-angle glaucoma/angle-closure glaucoma. The “angle” in both cases refers to the drainage angle inside the eye that controls the outflow of the watery fluid (aqueous) which is being produced inside the eye.

Open-angle glaucoma (OAG) is the most common form of the disease. The drainage angle formed by the cornea and iris remains open, but the trabecular meshwork is partially blocked. This causes pressure in the eye to increase gradually and damages the optic nerve. It happens so slowly that the patient may lose vision before they are even aware of a problem, while in the case of narrow-angle glaucoma, the structure inside the eye that allows fluid to drain normally from the eye (called the drainage angle) becomes restricted. Narrow drainage angles in the eye increase the risk of the drainage angle that gets blocked, resulting in a significant increase in eye pressure and risk of vision loss. If this occurs, narrow-angle glaucoma is usually called angle-closure glaucoma.

Glaucoma Epidemiology Perspective


The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalence of Glaucoma, Type-specific Diagnosed Prevalent Population of Glaucoma, Gender-specific Diagnosed Prevalence of Glaucoma, Age-specific Diagnosed Prevalence of Glaucoma, Type-specific Diagnosed Prevalence of Open-Angle Glaucoma scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2018 to 2030.

Glaucoma Detailed Epidemiology Segmentation

  • The total diagnosed prevalent population of Glaucoma in the 7MM was 10,104,188 in 2020 , which is expected to increase in the forecast period.
  • Among the European five countries, Germany had the highest diagnosed prevalent population of Glaucoma with 1,042,465 cases, followed by Italy and France in 2020. On the other hand, Spain had the lowest.
  • Japan had 2,886,961 diagnosed prevalent cases for Glaucoma in 2020.
“As per the analysis, a higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM countries. The highest proportion of Gluacoma cases was observed in 70-79 years age group in the US, while in the EU-5 countries, people aged =80 years accounted for the maximum patient pool. In contrast, middle age population aged 40-49 years contributed highest patient pool in Japan. Among the major types of Glaucoma, i.e., open-angle and close-angle glaucoma, the former one accounts for a higher number of diagnosed Glaucoma cases”.

Scope of the Report

  • The report covers the descriptive overview of Glaucoma, explaining its causes, symptoms, pathophysiology, and genetic basis.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Glaucoma.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Diagnosed Prevalence of Glaucoma, Type-specific Diagnosed Prevalent Population of Glaucoma, Gender-specific Diagnosed Prevalence of Glaucoma, Age-specific Diagnosed Prevalence of Glaucoma, Type-specific Diagnosed Prevalence of Open-Angle Glaucoma.

Report Highlights

  • 10-Year Forecast of Glaucoma
  • 7MM Coverage
  • Total Prevalent Cases of Glaucoma
  • Male and Female Cases of Glaucoma
  • Glaucoma Patients among different age groups

Key Questions Answered

  • What are the disease risk, and burden of Glaucoma ?
  • What is the historical Glaucoma patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Glaucoma at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Glaucoma ?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Glaucoma during the forecast period (2021-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021-2030)?

Reasons to Buy


The Glaucoma report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the 7MM Glaucoma epidemiology forecast.
  • The Glaucoma epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Glaucoma epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2018-2030
Note: Product cover images may vary from those shown
1 Key Insights

2 Report Introduction

3 Glaucoma Epidemiology Overview at a Glance
3.1 Patient Distribution (%) of Glaucoma in 2018
3.2 Patient Distribution (%) of Glaucoma in 2030

4 Executive Summary of Glaucoma

5 Disease Background and Overview
5.1 Introduction
5.2 Classification of Glaucoma
5.2.1 Classification of Open-Angle Glaucoma (OAG)
5.2.2 Classification of Close-Angle Glaucoma/Angle-closure glaucoma (ACG)
5.3 Signs and Symptoms of Glaucoma
5.3.1 Signs and Symptoms of Open-Angle Glaucoma
5.3.2 Signs and Symptoms of Closed-angle Glaucoma
5.4 Risk Factors of Glaucoma
5.4.1 Risk Factors associated with Primary Open-angle Glaucoma (POAG)
5.4.1.1 General
5.4.1.2 Ocular
5.4.1.3 Nonocular
5.4.1.4 Ocular Hypertension
5.4.2 Risk Factors associated with Closed-angle Glaucoma
5.5 Genes Involved in Glaucoma
5.5.1 Primary Open Angle Glaucoma
5.5.2 Primary Closed Angle Glaucoma (PACG)
5.6 Diagnosis
5.6.1 Diagnosis of Glaucoma
5.6.2 Diagnostic criteria of Angle Closure Glaucoma
5.6.3 Differential Diagnosis of Glaucoma
5.6.4 Diagnostic Algorithm for Glaucoma
5.6.5 Primary Glaucoma Preferred Practice Pattern guidelines

6 Epidemiology and Patient Population
6.1 Key Findings
6.2 Epidemiology Methodology
6.3 Total Diagnosed Prevalence of Glaucoma in the 7MM
6.4 Epidemiology of Glaucoma
6.5 The United States
6.5.1 Total Diagnosed Prevalence of Glaucoma in the United States
6.5.2 Type-specific Diagnosed Prevalent Population of Glaucoma in the United States
6.5.3 Gender-specific Diagnosed Prevalence of Glaucoma in the United States
6.5.4 Age-specific Diagnosed Prevalence of Glaucoma in the United States
6.5.5 Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States
6.6 EU5
6.6.1 Germany
6.6.1.1 Total Diagnosed Prevalence of Glaucoma in Germany
6.6.1.2 Type-specific Diagnosed Prevalent Population of Glaucoma in Germany
6.6.1.3 Gender-specific Diagnosed Prevalence of Glaucoma in Germany
6.6.1.4 Age-specific Diagnosed Prevalence of Glaucoma in Germany
6.6.1.5 Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany
6.6.2 France
6.6.2.1 Total Diagnosed Prevalence of Glaucoma in France
6.6.2.2 Type-specific Diagnosed Prevalent Population of Glaucoma in France
6.6.2.3 Gender-specific Diagnosed Prevalence of Glaucoma in France
6.6.2.4 Age-specific Diagnosed Prevalence of Glaucoma in France
6.6.2.5 Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in France
6.6.3 Italy
6.6.3.1 Total Diagnosed Prevalence of Glaucoma in Italy
6.6.3.2 Type-specific Diagnosed Prevalent Population of Glaucoma in Italy
6.6.3.3 Gender-specific Diagnosed Prevalence of Glaucoma in Italy
6.6.3.4 Age-specific Diagnosed Prevalence of Glaucoma in Italy
6.6.3.5 Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy
6.6.4 Spain
6.6.4.1 Total Diagnosed Prevalence of Glaucoma in Spain
6.6.4.2 Type-specific Diagnosed Prevalent Population of Glaucoma in Spain
6.6.4.3 Gender-specific Diagnosed Prevalence of Glaucoma in Spain
6.6.4.4 Age-specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain
6.6.4.5 Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain
6.6.5 United Kingdom
6.6.5.1 Total Diagnosed Prevalence of Glaucoma in the United Kingdom
6.6.5.2 Type-specific Diagnosed Prevalent Population of Glaucoma in the United Kingdom
6.6.5.3 Gender-specific Diagnosed Prevalence of Glaucoma in the United Kingdom
6.6.5.4 Age-specific Diagnosed Prevalence of Glaucoma in the United Kingdom
6.6.5.5 Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom
6.7 Japan
6.7.1 Total Diagnosed Prevalence of Glaucoma in Japan
6.7.2 Type-specific Diagnosed Prevalent Population of Glaucoma in Japan
6.7.3 Gender-specific Diagnosed Prevalence of Glaucoma in Japan
6.7.4 Age-specific Diagnosed Prevalence of Glaucoma in Japan
6.7.5 Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan

7 Patient Journey

8 KOL Views

9 Appendix
9.1 Report Methodology

10 Publisher Capabilities

11 Disclaimer

12 About the Publisher

List of Tables
Table 1: Summary of Glaucoma Epidemiology, and Key Events (2018–2030)
Table 2: Two Classes of Primary Open-Angle Glaucoma (POAG) Mutations
Table 3: Genes associated with the risk of POAG
Table 4 : Genes identified in linkage or association with PACG
Table 5: Differential Diagnosis for Glaucoma
Table 6: The definitions and levels of evidence to rate individual studies
Table 7: Recommendations for care are formed based on the body of the evidence. The body of evidence quality ratings are defined by GRADE
Table 8: Primary Open-Angle Glaucoma Preferred Practice Pattern guidelines
Table 9: Primary Closed-Angle Glaucoma Preferred Practice Pattern guidelines
Table 10: Total Diagnosed Prevalence of Glaucoma in the 7MM (2018–2030)
Table 11: Total Diagnosed Prevalence of Glaucoma in the United States (2018–2030)
Table 12: Type-specific Diagnosed Prevalent Population of Glaucoma in the US (2018–2030)
Table 13: Gender-specific Diagnosed Prevalence of Glaucoma in the US (2018–2030)
Table 14: Age-specific Diagnosed Prevalence of Glaucoma in the United States (2018–2030)
Table 15: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States (2018–2030)
Table 16: Total Diagnosed Prevalence of Glaucoma in Germany (2018–2030)
Table 17: Type-specific Diagnosed Prevalent Population of Glaucoma in Germany (2018–2030)
Table 18: Gender-specific Diagnosed Prevalence of Glaucoma in Germany (2018–2030)
Table 19: Age-specific Diagnosed Prevalence of Glaucoma in Germany (2018–2030)
Table 20: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2018–2030)
Table 21: Total Diagnosed Prevalence of Glaucoma in France (2018–2030)
Table 22: Type-specific Diagnosed Prevalent Population of Glaucoma in France (2018–2030)
Table 23: Gender-specific Diagnosed Prevalence of Glaucoma in France (2018–2030)
Table 24: Age-specific Diagnosed Prevalence of Glaucoma in France (2018–2030)
Table 25: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2018–2030)
Table 26: Total Diagnosed Prevalence of Glaucoma in Italy (2018–2030)
Table 27: Type-specific Diagnosed Prevalent Population of Glaucoma in Italy (2018–2030)
Table 28: Gender-specific Diagnosed Prevalence of Glaucoma in Italy (2018–2030)
Table 29: Age-specific Diagnosed Prevalence of Glaucoma in Italy (2018–2030)
Table 30: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2018–2030)
Table 31: Total Diagnosed Prevalence of Glaucoma in Spain (2018–2030)
Table 32: Type-specific Diagnosed Prevalent Population of Glaucoma in Spain (2018–2030)
Table 33: Gender-specific Diagnosed Prevalence of Glaucoma in Spain (2018–2030)
Table 34: Age-specific Diagnosed Prevalence of Glaucoma in Spain (2018–2030)
Table 35: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2018–2030)
Table 36: Total Diagnosed Prevalence of Glaucoma in the UK (2018–2030)
Table 37: Type-specific Diagnosed Prevalent Population of Glaucoma in the UK (2018–2030)
Table 38: Gender-specific Diagnosed Prevalence of Glaucoma in the UK (2018–2030)
Table 39: Age-specific Diagnosed Prevalence of Glaucoma in the UK (2018–2030)
Table 40: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in the UK (2018–2030)
Table 41: Total Diagnosed Prevalence of Glaucoma in Japan (2018–2030)
Table 42: Type-specific Diagnosed Prevalent Population of Glaucoma in Japan (2018–2030)
Table 43: Gender-specific Diagnosed Prevalence of Glaucoma in Japan (2018–2030)
Table 44: Age-specific Diagnosed Prevalence of Glaucoma in Japan (2018–2030)
Table 45: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2018–2030)

List of Figures
Figure 1: Classification of Glaucoma
Figure 2: Classification of Open-Angle Glaucoma
Figure 3: Glaucoma classification and subtypes.
Figure 4: Symptoms of Open-Angle Glaucoma
Figure 5: Symptoms of Closed-angle Glaucoma
Figure 6: Risk Factors Associated with POAG
Figure 7 : Proposed pathways for normal secretion of myocilin into the aqueous humor and for secretion reduced by an MYOC mutation
Figure 8: Diagnosis of Glaucoma
Figure 9: Glaucoma Assessment (Optic Nerve)
Figure 10: Clinical findings that define patients seen with Angle-Closure disease
Figure 11: Evaluation of a glaucoma suspect (open-angle glaucoma)
Figure 12: Evaluation of a glaucoma suspect (angle-closure disease)
Figure 13: Total Diagnosed Prevalence of Glaucoma in the 7MM (2018–2030)
Figure 14: Total Diagnosed Prevalence of Glaucoma in the United States (2018–2030)
Figure 15: Type-specific Diagnosed Prevalent Population of Glaucoma in the US (2018–2030)
Figure 16: Gender-specific Diagnosed Prevalence of Glaucoma in the US (2018–2030)
Figure 17: Age-Specific Diagnosed Prevalence of Glaucoma in the United States (2018–2030)
Figure 18: Type-specific Diagnosed Prevalence of Open-angle Glaucoma in the United States (2018–2030)
Figure 19: Total Diagnosed Prevalence of Glaucoma in Germany (2018–2030)
Figure 20: Type-specific Diagnosed Prevalent Population of Glaucoma in Germany (2018–2030)
Figure 21: Gender-specific Diagnosed Prevalence of Glaucoma in Germany (2018–2030)
Figure 22: Age-specific Diagnosed Prevalence of Glaucoma in Germany (2018–2030)
Figure 23: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2018–2030)
Figure 24: Total Diagnosed Prevalence of Glaucoma in France (2018–2030)
Figure 25: Type-specific Diagnosed Prevalent Population of Glaucoma in France (2018–2030)
Figure 26: Gender-specific Diagnosed Prevalence of Glaucoma in France (2018–2030)
Figure 27: Age-specific Diagnosed Prevalence of Glaucoma in France (2018–2030)
Figure 28: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2018–2030)
Figure 29: Total Diagnosed Prevalence of Glaucoma in Italy (2018–2030)
Figure 30: Type-specific Diagnosed Prevalent Population of Glaucoma in Italy (2018–2030)
Figure 31: Gender-specific Diagnosed Prevalence of Glaucoma in Italy (2018–2030)
Figure 32: Age-specific Diagnosed Prevalence of Glaucoma in Italy (2018–2030)
Figure 33: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2018–2030)
Figure 34: Total Diagnosed Prevalence of Glaucoma in Spain (2018–2030)
Figure 35: Type-specific Diagnosed Prevalent Population of Glaucoma in Spain (2018–2030)
Figure 36: Gender-specific Diagnosed Prevalence of Glaucoma in Spain (2018–2030)
Figure 37: Age-specific Diagnosed Prevalence of Glaucoma in Spain (2018–2030)
Figure 38: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2018–2030)
Figure 39: Total Diagnosed Prevalence of Glaucoma in the UK (2018–2030)
Figure 40: Type-specific Diagnosed Prevalent Population of Glaucoma in the UK (2018–2030)
Figure 41: Gender-specific Diagnosed Prevalence of Glaucoma in the UK (2018–2030)
Figure 42: Age-specific Diagnosed Prevalence of Glaucoma in the UK (2018–2030)
Figure 43: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in the UK (2018–2030)
Figure 44: Total Diagnosed Prevalence of Glaucoma in Japan (2018–2030)
Figure 45: Type-specific Diagnosed Prevalent Population of Glaucoma in Japan (2018–2030)
Figure 46: Gender-specific Diagnosed Prevalence of Glaucoma in Japan (2018–2030)
Figure 47: Age-specific Diagnosed Prevalence of Glaucoma in Japan (2018–2030)
Figure 48: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2018–2030)
Note: Product cover images may vary from those shown
Adroll
adroll